Prevalence and Overlap of Cardiovascular, Kidney, and Metabolic Diseases in Korea: A Population-based Study
← catalyst calendarSponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
—
Status
Enrolling by invitation
Study type
Observational
Enrollment
800,000estimated
Sites
1
Country
South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-08 | actual | When the study began enrolling |
| Primary completion | 2026-08-03 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-08-03 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Diabetes Mellitus, Type 2
- Obesity
- Chronic Kidney Disease
- Cardiovascular Risk
Intervention
- Other: No treatment given
Primary outcomes
what the primary-completion date above is the date OFProportion of participants with obesity (BMI ≥25 kilograms per square meter (kg/m^2))
measured 2013-2018 (Annually)
Proportion of participants with T2D
measured 2013-2018 (Annually)
Proportion of participants with hypertension
measured 2013-2018 (Annually)
Proportion of participants with dyslipidemia
measured 2013-2018 (Annually)
Proportion of participants with CVD (ASCVD, HF with atrial fibrillation, HF without atrial fibrillation)
measured 2013-2018 (Annually)
Proportion of participants with CKD
measured 2013-2018 (Annually)
Proportion of participants with MASLD; at-risk Metabolic Dysfunction-Associated Steatohepatitis (MASH)(within MASLD)
measured 2013-2018 (Annually)
Proportion of participants with Osteoarthritis (OA)
measured 2013-2018 (Annually)
Multi-disease overlap (≥2, ≥3 conditions)
measured 2013-2018 (Annually)
Patient characteristics in obesity/diabetes-anchored strata
measured 2013-2018 (Annually)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed